R/R MDS

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study or Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies With an IDH1 Mutation, With a Substudy in Subjects With Relapsed or Refractory Myelodysplastic Syndrome and a Substudy in Subjects With Advanced Hematologic Malignancies With Organ Impairment